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Abstract 
Nanotechnology represents a new and enabling platform that promises to provide a range 
of innovative technologies for biological applications.  ZnO nanoparticles of controlled 
size were synthesized, and their cytotoxicity towards different human immune cells 
evaluated.  A differential cytotoxic response between human immune cell subsets was 
observed, with lymphocytes being the most resistant and monocytes being the most 
susceptible to ZnO nanoparticle-induced toxicity.  Significant differences were also 
observed between previously activated memory lymphocytes and naive lymphocytes, 
indicating a relationship between cell-cycle potential and nanoparticle susceptibility. 
Mechanisms of toxicity involve the generation of reactive oxygen species, with monocytes 
displaying the highest levels, and the degree of cytotoxicity dependent on the extent of 
nanoparticle interactions with cellular membranes. An inverse relationship between 
nanoparticle size and cytotoxicity, as well as nanoparticle size and reactive oxygen species 
production was observed.  In addition, ZnO nanoparticles induce the production of the 
proinflammatory cytokines, IFN-γ, TNF-α and IL-12, at concentrations below those 
causing appreciable cell death. Collectively, these results underscore the need for careful 
evaluation of ZnO nanoparticle effects across a spectrum of relevant cell types when 
considering their use for potential new nanotechnology-based biological applications. 
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Introduction 
Nanotechnology permits the manipulation of matter at the nanometer scale which enables precision 
engineering to control nanomaterial physiochemical properties as well as their interactions with biological 
systems.  It is the alterations in electrical, magnetic, structural, morphological, chemical, and physical 
properties of nanomaterials, which are comparable in size to naturally occurring biomolecules, that makes 
them particularly attractive for pioneering applications in technological and biological applications [1-4].  
Nanomaterials comprised of ZnO have received considerable attention in recent years because of their 
potential use in electronic and industrial applications arising from their wide band-gap (3.36 eV) 
semiconductor properties [3]. From a biological perspective, nanoscale ZnO materials are already being 
used in the cosmetic and sunscreen industry due to their transparency and ability to reflect, scatter, and 
absorb UV radiation, and as food additives [5,6].  ZnO nanomaterials are also being considered for use in 
next-generation biological applications including antimicrobial agents, drug-delivery, bioimaging probes 
and cancer treatment  [7-10].  Although bulk (micron-sized) ZnO is generally recognized as a GRAS 
substance by the FDA [5,6], many benign materials can exhibit appreciable cellular toxicity when reduced 
to the nanoscale [11].  Recent toxicological studies using certain engineered nanoparticles (NPs) have 
confirmed the potentially harmful effects due to their high surface area, unique physiochemical properties, 
and increased reactivity of the material’s surface [11,12]. This has led to the term, nanotoxicology, which 
describes the relationship between nanoparticle physiochemical properties, and toxicological effects on 
living cells and biological systems. 
 
In this regard, several recent reports have demonstrated the toxicity of metal-oxide NPs to both prokaryotic 
and eukaryotic cellular systems [7,7,10,13-16], while the bulk micron-sized materials remain non-toxic. 
The majority of eukaryotic studies specific to ZnO NPs, however, have relied heavily on the use of 
immortalized cells lines, which are recognized to display altered sensitivities to foreign materials/chemicals 
due to alterations in metabolic processes and major genetic instabilities.  To date, only limited studies have 
evaluated the toxicity of ZnO NPs on normal primary human cells and their potential immunomodulatory 
effects. Even more challenging is the fact that the cytotoxic response is very different between cell types 
and nanomaterial systems, making it difficult to develop predictive models without detailed and systematic 
investigations. Recent reports demonstrate that ZnO NPs display differential toxicity towards primary 
human cells depending upon their proliferation potential, with normal T lymphocytes that are stimulated to 
divide by signaling through the T cell receptor displaying significantly greater toxicity than quiescent 
nonproliferating cells of identical lineage [13].  When these studies were extended to immortalized T 
leukemic and lymphoma cells using identical ZnO NPs, an even greater sensitivity to NP-induced toxicity 
was observed (~33-fold) [13].  Thus, susceptibility to NP-induced cytotoxicity appears to be related to the 
proliferative capacity of the cell, and may also be affected by other physiologically relevant parameters, 
including cell-NP electrostatic interactions and inherent differences in cellular endocytic/phagocytic 
processes that facilitate NP uptake.  These variations in cytotoxic response indicate that a more detailed and 
carefully controlled evaluation of ZnO NP effects on multiple types of normal human cells is needed to 
better understand the biological consequences of NP exposure.  In addition, it is increasingly being 
recognized that toxicity depends on nanomaterial characteristics including size, shape, and electrostatic 
charge, as well as materials composition [7,10,17,18].  In this study, the evaluation of size-controlled ZnO 
NPs and their resulting toxicity on different cells comprising the human immune system is explored.  In 
addition, mechanisms underlying the differential toxicity response are investigated, as well as effects of 
ZnO NPs to induce pro-inflammatory cytokine expression. 
 
Experimental 
 
Preparation and Characterization of ZnO Nanoparticles 
ZnO NPs utilized in all experiments were synthesized in diethylene glycol (DEG) via forced hydrolysis of 
zinc acetate [14]. In brief, zinc acetate was dissolved in DEG, and then nanopure water was added under 
magnetic stirring. Subsequently, the system was heated at 160 ºC under reflux for 90 min. After cooling, 
the resulting product was removed from DEG via centrifugation, and washed with ethanol several times 
before drying for 24 hours at 50°C, resulting in a powder sample. The sample crystal phase, crystallite size, 
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and morphology were characterized via x-ray diffraction (XRD) and transmission electron microscopy 
(TEM) as previously described [13,14]. The NPs were then weighed and reconstituted in phosphate 
buffered saline (PBS) solution to the desired stock concentration. After reconstitution, NPs were sonicated 
for 10 minutes and immediately vortexed prior to addition to cell cultures.  
 
Isolation of Peripheral Blood Mononuclear Cells   
For isolation of PBMC (peripheral blood mononuclear cells) and immune cell subsets, written informed 
consent was obtained from all blood donors.  The University Institutional Review Board approved this 
study. PBMC were obtained via Ficoll-Hypaque (Histopaque-1077, Sigma, St Louis, MO) gradient 
centrifugation using heparinized phlebotomy samples [19]. After removal of the leukocyte layer, cells were 
washed three times with Hank’s buffer (Sigma, St. Louis, MO) and resuspended at a final concentration of 
1 x 106 cells/ml in RPMI-1640 (Sigma) containing 10% fetal bovine serum (FBS) and cultured at 37° C and 
5% CO2. 
 
Isolation and Culture of Primary CD14+ Monocytes and CD4+ T cells 
PBMC were obtained by Ficoll-Hypaque density centrifugation as described above, and CD14+ cells 
isolated from the mixed cell suspension.  Negative immunomagnetic selection was performed according to 
the manufacturer’s protocol using a cocktail of antibodies directed against CD2, CD3, CD16, CD19, CD20, 
CD56, CD66b, CD123, and glycophorin A (StemCell Technologies, Vancouver, BC). For optimal cell 
recovery, PBMC were first blocked with anti-human CD32 (Fcγ RII) blocker reagent before labeling with 
the antibody cocktail. Purified CD14+ monocytes populations were typically of >92% purity and >97% 
viable as assessed by flow cytometry and cultured in RPMI/10% FBS at 5 x 105 cells/ml in 96-well plates 
at 37° C and 5% CO2.  
 
CD4+ T cells were purified from PBMC using negative immunomagnetic selection per manufacturer’s 
instructions and a cocktail of antibodies directed against CD8, CD14, CD16, CD19, CD56, and glycophorin 
A surface markers (StemCell Technologies).  Unlabeled T cells were collected (typically >97% purity and 
> 95% viable as assessed by flow cytometry) and subsequently cultured in RPMI/10% FBS at a final 
concentration of 1 x 106 cells/ml.  
 
Flow Cytometry  
Methods of immunofluorescent staining and flow cytometric analysis were performed as previously 
described [19] using a 4-color Epics XL flow cytometer (Beckman Coulter, Miami, FL). Cells were stained 
with fluorescently labeled antibodies (Beckman Coulter) for 30 min at 4°C, washed two times, and 
immediately analyzed. Ten thousand events gated on the parameter of size (forward scatter, or FS) and 
granularity (side scatter, or SSC) were analyzed, and expression of the percentage of positively staining 
cells and the mean fluorescence intensity (MFI) determined by comparisons to isotype controls. 
Appropriate concentrations of each antibody were determined by titration for optimal staining prior to 
experimental use. In PBMC cultures, individual cell types were distinguished from one another based on 
differential antibody staining and on FS and SSC properties.  T cells were defined as CD3+; T helper cells 
defined as CD3+,CD4+; naïve T cells defined as CD3+,CD45RA+; memory T cells defined as 
CD3+,CD45RO; B cells defined as CD19+,CD3;  NK cells defined as CD56+,CD16+,CD3-, and monocytes 
defined as CD14+,CD3-.  To prevent indiscriminate antibody staining of monocytes via Fc receptors, 100 µl 
of heat-inactivated human AB serum was added to experimental samples immediately prior to staining. 
 
Cell Viability Assays 
Cell viability following NP treatment was assessed using two different assays.  In the first assay, cell 
subsets were identified using fluorescently labeled antibodies, and viability was determined by staining 
with 50 µg/ml of propidium iodide (PI) to monitor losses in cell membrane integrity. Fluorescent 
CountBright counting beads (Invitrogen, Carlsbad, CA) were added to samples to enable determinations of 
absolute cell numbers, and flow cytometry was used to evaluate changes in PI staining and to quantify cell 
death.  NPs were excluded from the analysis based on absence of fluorescence signal and light FS and SSC 
characteristics.  
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The second viability assay employed the fluorogenic redox indicator dye, Alamar Blue.  This dye becomes 
fluorescent upon reduction by mitochondrial enzymes in metabolically active cells. Cell populations were 
seeded into 96-well plates at 5 x 105 cells/ml, treated with ZnO NP for 18h, and  20 µl of Alamar Blue 
added to cultures for an additional 6h. Changes in fluorescence were evaluated spectrophotometrically 
using excitation/emission at 530/590 nm. 
 
ROS Detection 
To assay for NP-induced reactive oxygen species (ROS) production, cells were first obtained from whole 
blood treated with an ammonium chloride lysing solution (1.5 M NH4Cl, 0.1 M NaHCO3, 0.01 EDTA) to 
lyse red blood cells, and centrifuged for 10 min at 4°C to remove erythrocytic debris. The white blood cells 
were then resuspended in phenol red-free RPMI to a final concentration of 1 x 106 cells/ml, and incubated 
with ZnO NPs for 6h to 20h. Cells were subsequently loaded with 5 µM of the oxidation-sensitive dye, 
2’,7’-dichlorofluorescein diacetate (DCFH-DA, Invitrogen, Carlsbad, CA) for 20 min.  Production of the 
oxidation product was evaluated using flow cytometry as previously described [20].  White blood cell 
populations (i.e., CD3+ T cells and CD14+,CD3- monocytes) present in the samples were simultaneously 
evaluated based on FS and SSC gating and staining with appropriate fluorescently labeled antibodies.  As a 
positive control for ROS production, control cells were loaded with DCFH-DA dye and activated with 
PMA (25 ng/mL) for 1h.  For studies described in Figure 7, ROS production was evaluated in PBMC 
treated with different-sized ZnO NPs using a fluorescent microplate reader as previously described [21,22]. 
Experimental methodology, including the use of the DCFH-DA dye to indicate ROS generation, was 
identical as described above. 
 
To determine the role of ROS in NP-induced cell death, purified primary CD4+ T cells and monocytes were 
seeded in a 96-well plate at 5 x 105 cells/ml and pre-treated with  5 mM of the ROS scavenger, N-acetyl 
cysteine (NAC, Sigma), for 4-6h. Cultures were then treated with various concentrations of ZnO NP for 
24h and viability was determined using the Alamar Blue cytotoxicity assay and a fluorescent microplate 
reader.  
 
Cytokine Analysis 
To investigate the effect of ZnO NPs on cytokine production, an ELISA (enzyme linked immunosorbent 
assay) was used.  For determination of  IFN-γ and TNF-α  production, freshly isolated PBMC were 
cultured at 1 x 106 cells/mL, and treated with varying concentrations of 8-nm ZnO NPs (0.05 mM, 0.1 mM 
and 0.2 mM) for 38h.  For determination of IL-12 levels, PBMC cultures were either left untreated or 
pretreated with 1000 U/mL of IFN-γ (Peprotech, Rocky Hill, NJ), to prime for the production of this 
cytokine, and then cultured with ZnO NPs for 24h.  After NP treatment, cell-free supernatants were 
harvested via successive 10-min centrifugations (2,000 rpm, 7,000 rpm and 13,000 rpm) and stored at -
80°C until analysis. ELISA was performed by the UMAB Cytokine Core Laboratory (Baltimore, MD), 
with all samples analyzed in triplicate. 
 
Statistical Analyses  
All data was analyzed using SAS, Inc. software (Cary, NC). Data for figures 3, 4, and 6 was analyzed using 
repeated measures of variance with post hoc comparisons to allow within-subject variation to be separated 
from between-subject variation. Data for figures 5, 7 and 8 was analyzed using a two-way analysis of 
variance (ANOVA).  In all cases, significance levels were defined as p < 0.05. 
 
Results and Discussion 
 
Synthesis and Size Control of ZnO Nanoparticles 
To evaluate the relationship between NP size and cytotoxic properties on various types of immune cells, 
ZnO NPs (4-20 nm) were synthesized by modifying the hydrolysis molar ratio of water to zinc acetate.  
Transmission electron microscopy (TEM) measurements shown in Figure 1a-d demonstrate that the use of 
hydrolysis ratios (water:zinc acetate) of 2.4, 6.1, 12.2, and 24.4 yields NPs with  average diameters of 4 to 
8, 13, and 20 nm, respectively. The 4 nm NP produced by this synthesis method are of roughly spherical in 
morphology while NPs ≥ 8 nm acquire a rod-shaped morphology. The corresponding particle-size 
  
C. Hanley, A. Thurber, C. Hanna, A. Punnoose, J. Zhang, & D. G. Wingett in NANOSCALE RESEARCH LETTERS (2009)  5 
This is an author-produced, peer-reviewed version of this article.  The final, definitive version of this document can be found online 
at Nanoscale Research Letters, published by Springer.  Copyright restrictions may apply.  doi: 10.1007/s11671-009-9413-8 
histogram (Figure 1e) shows that all of the ZnO samples have a narrow size distribution. The x-ray 
diffraction (XRD) patterns shown in Figure 2 indicate that all of the ZnO samples are well-indexed to the 
pure wurtzite crystallite phase of ZnO, demonstrating that the sample is comprised of ZnO nanocrystals. 
Furthermore, the average crystallite sizes estimated using the peak widths (full width at half maximum) of 
the XRD patterns agree well with TEM results for both size and shape, where the average aspect ratio of 
NPs > 8nm increases up to 2 (Figure  2 inset).   
 
T and B Lymphocytes are More Resistant to NP Toxicity Compared to Monocytes and NK Cells 
Previous studies from our laboratory have determined that rapidly dividing cancerous T cells are more 
susceptible to ZnO NP toxicity than normal quiescent T cells [13].  These finding were extended to 
determine whether NP toxicity might also vary between different types of normal cells comprising the 
human immune system including T cells, B cells, natural killer (NK) cells, and monocytes.  For these 
studies, freshly isolated peripheral blood mononuclear cell (PBMC) preparations were used, since all of the 
desired cell types for study are present in the same culture allowing for a well-controlled and uniform NP 
exposure. Following 24h NP treatment, the various cell types were identified by staining with antibodies 
specific for T, B, NK or monocyte surface markers, and NP-induced cytotoxicity was assessed using 
propidium iodide (PI), which is a red fluorescent nuclear stain that selectively enters cells with disrupted 
plasma membranes. As shown in Figure 3A, differences in NP-induced cytotoxicity were apparent with 
lymphocytes (CD3+ T cells, CD4+ T cells, and B cells) displaying the most resistance.  All of these 
lymphocyte populations displayed similar IC50 values (~ 5.0 mM), with no significant difference observed 
between them at any NP concentration evaluated.   In contrast, NK cells were substantially more sensitive 
to NP-induced cytotoxicity, with an IC50 of ~1.0 mM.  Statistically significant differences were detected 
between NK cells and B and T lymphocytes at 1- 5 mM NP concentrations (e.g., p = 0.003 at 1 mM, p = 
0.0002 at 2.5 mM, p = 0.002 at 5 mM, and p = 0.05; NK cells vs. CD3+ T cells at 10 mM NP).  Most 
striking is the increased NP-induced cytotoxicity observed in monocytes, with >50% of the monocytes 
killed at the lowest NP concentration tested (0.5 mM).  Statistically significant differences were observed 
between monocytes and NK cells (0.5 mM and 1 mM; p = 0.0002 and p = 0.0008, respectively), and 
monocytes compared to T and B lymphocytes (p<0.0001 for both cell types at both concentrations tested).  
  
Because adherent monocytes appear considerably more susceptible to NP-induced cytotoxicity compared to 
other immune cell subsets, additional experiments were performed using purified monocytes and lower 
concentrations of NP, to more accurately determine the IC50 value.  In these experiments, monocytes were 
treated with varying concentrations of ZnO NPs, and viability was evaluated using the fluorogenic redox 
Alamar Blue cytotoxicity assay. In agreement with monocyte data obtained from PBMC cultures, an IC50 
of ∼0.30 mM was observed (Figure 3B). The Alamar Blue cytotoxicity assay was also used to confirm the 
IC50 using purified CD4+ T cells, and a similar IC50 value of ∼5.4 was observed (data not shown).  As 
previously reported by our lab [13,14,23], control experiments using bulk micron-sized ZnO powder 
showed no appreciable toxicity effect at any of the concentrations tested (e.g., viability with bulk ZnO: 96 
± 3% at 1 mM, 93 ± 3% at 10 mM), demonstrating that toxicity is limited to nanoscale ZnO.  In addition, 
no appreciable toxicity was observed using NP-free supernatants (e.g., 98% viability with NP-free 
supernatant equivalent to 1-10 mM), indicating that the toxicity is likely not due to dissolved Zn ions from 
NP preparations.  
 
Although these results indicate that monocytes are considerably more susceptible to NP-induced 
cytotoxicity than other immune cell types tested, it is important to note that these differences may be 
related to distinctions in cell-culture conditions. While T cells, B cells and NK cells grow as suspension 
cultures, cultured monocytes grow as an adherent monolayer. These differences in growth characteristics 
may act to increase the effective ZnO NP concentration in adherent cultures. It is also plausible that the 
inherently greater capacity of adherent monocytes to phagocytose foreign materials, including NPs, may 
underlie their greater sensitivity, and the inherent cytolytic activity of NK cells against foreign pathogens 
and altered self-cells may contribute to their greater sensitivity compared to lymphocyte populations. To 
address these possibilities, future experiments involving 3-dimensional cell culture systems and those 
evaluating the extent to which phagocytic/endocytic mechanisms contribute to cell-type differences are 
needed. Nevertheless, given the variable susceptibilities of different immune cell types to ZnO NPs, it 
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seems clear that careful analysis of in vitro cellular systems, followed by appropriate in vivo studies, is 
necessary to provide thorough and possibly predictive screening data regarding the relative toxicity and 
immunomodulatory effects of ZnO NP. 
 
Memory and Naïve T cells Differ in Cytotoxic Response to ZnO NP 
Our previous findings that ZnO NP toxicity is dependent on the cell activation status, with quiescent T cells 
being more resistant to ZnO NP-induced cytotoxicity than identical cells activated to divide via stimulation 
through the T cell receptor [13], led us to evaluate whether “memory” T cells display greater sensitivity to 
ZnO NPs than “naïve” T cells.  During an immune response, the activation of T cells to a specific antigen 
found on a pathogen results in a cascade of intracellular signaling events, and to the differentiation of naïve 
T cells into memory cells.  Once memory cells have formed, they can become activated to proliferate much 
more readily upon subsequent exposure to the original antigen [24].  This occurs because memory T cells 
require lower activation signals/thresholds to proliferate which is due, at least in part,  to alterations in 
intracellular calcium mobilization and calcium-dependent signaling processes [25,26].   
 
To assess potential susceptibilities of naïve and memory T cell populations to ZnO NPs in a well-controlled 
environment, PBMC (which contained both naïve and memory T cells) were treated with 8-nm ZnO NPs 
for 22-24 h, with the viability assessed by PI uptake using flow cytometry. Naïve CD3+ T cells 
(CD45RA+,CD3+) were identified based on the expression of the CD45RA surface marker, while memory 
T cells (CD45RO+,CD3+) were  identified based on expression of the distinguishing CD45RO surface 
marker [26,27].  Cytotoxic responses were then compared to bulk cultures of CD3+ T cells containing both 
naïve and memory cells from the same blood donor. As shown in Figure 4,  memory T cells displayed 
significantly greater sensitivity to NP toxicity than either naive T cells or bulk cultures of CD3+ T  cells  (p 
= 0.0044  and p = 0.0244) at 10 mM ZnO NP concentration.  Naïve T cells appeared more resistant than 
CD3+ T cells, although statistically significant differences were not observed (p = 0.08). These results 
demonstrate that even subsets of T cells show measureable differences in cytotoxic response to ZnO NP, 
which appears related to their activation threshold and/or proliferation potential.  
ZnO NP Induce ROS Production in Monocytes and T Cells 
Reactive oxygen species (ROS) are produced by cells as part of normal metabolic processes.  However, in 
situations where ROS production exceeds the cell’s antioxidant capability, cell death can occur by 
interfering with normal physiological processes and the modification of cellular biomolecules [28].  
Recently, several types of nanomaterials including quantum dots and metal-oxide NPs have been shown to 
induce intracellular generation of ROS [13,15,16,29], although only limited studies have evaluated the 
ability of ZnO NPs to induce ROS in normal/non-transformed human cells. To investigate oxidative stress 
as a mechanism of ZnO NP-induced cellular toxicity in normal immune cell populations, studies compared 
ROS production between primary monocytes and T cells.   Based on the differing sensitivities of these two 
cell populations, two different concentrations of ZnO NPs were used (i.e., 1 mM and 5 mM). ROS 
generation was evaluated using the cell permeabilty dye, DCFH-DA, which is oxidatively modified into a 
highly fluorescent derivative by ROS including superoxide anion and hydrogen peroxide.  Studies were 
performed using mixed PBMC cultures to allow for identical NP-treatment conditions, and cell 
identification was determined by staining with fluorescently labeled antibodies directed towards the CD3 
and CD14 surface markers.  Flow cytometry was then used to simultaneously identify monocytes and T 
cells, as well as their corresponding level of ROS production at both early and extended exposure times. As 
shown in Table 1, there was a modest amount of ROS produced in monocytes treated with 1 mM NP (19% 
ROS producing cells) as early as 6h post ZnO NP exposure, yet no detectable ROS was observed in T cells 
at the corresponding NP concentration and time point. However, at 20h of treatment, appreciable ROS 
production was observable in T cells (~38% ROS producing cells at 5 mM ZnO NP), yet no residual cell-
associated ROS signal was observed in monocytes as nearly complete cell death was noted.  These results 
indicate that ZnO NPs are capable of inducing intracellular ROS in both cell types, although ROS 
production in monocytes occurs considerably earlier than for T cells, which may mechanistically underlie 
their greater sensitivity to ZnO NPs.  
 
 
ROS Quenchers Rescue Primary Monocytes and T Cells from ZnO NP Induced Cytotoxicity 
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Experiments were then performed to determine the causal role of NP-induced ROS as a major mechanism 
of toxicity. Purified human CD14+ monocytes and CD4+ T cells were pre-treated with N-acetyl cysteine 
(NAC), a well-known ROS quenching agent [30], prior to ZnO NP exposure. Following 24h of ZnO NP  
treatment, cell viability was assessed using the Alamar Blue cytotoxicity assay.  Figure 5 reveals that 5 mM 
NAC significantly protects both monocytes and CD4+ T cells against cell death (p = 0.0001 and p = 0.0481, 
respectively), and implicates ROS formation as a major mechanism of ZnO NP-induced toxicity in primary 
immune cells.  
 
ZnO NP Preferentially Associate with Monocytes Compared to Lymphocytes 
Experiments were performed to gain insights into the mechanisms underlying the greater susceptibility of 
monocytes to NP-induced cytotoxicity, by evaluating the extent to which NPs preferentially associate with 
these cells.  FITC-encapsulated ZnO NPs (FITC-ZnO NPs) were prepared as previously described by our 
group [23], and their fluorescence properties were used to monitor the extent to which they physically and 
stably associate with cells.  Freshly isolated PBMC were treated with 5 mM FITC-ZnO NP, or left 
untreated, and multi-color flow cytometry was used to  simultaneous identify monocytes and lymphocyte 
populations present in the PBMC culture, as well as the relative increase in the FITC-NP signal.  As shown 
in Table 2, all immune-cell types evaluated showed a strong association with NPs, with 78-98% of cells 
displaying at least some level of positive FITC fluorescence compared to control cells cultured in the 
absence of NPs.   However, a 9.3-13.7 - fold increase in the number of NP associating with any given 
monocyte compared to individual T or B lymphocytes was observed, as indicated by changes in mean 
fluorescence intensity (MFI) values. These results demonstrate that ZnO NPs preferentially associate with 
monocytes (MFI: 131.2), compared to lymphocyte subpopulations (MFI: 9.84 for CD3+ T cells, MFI: 14.1 
for CD4+ T cells and MFI: 9.61 for B cells).  The greater NP association with monocytes may arise through 
either extracellular membrane-NP interactions or intracellular NP uptake, as we have previously reported 
the ability of these same FITC-encapsulated NPs to be intracellularly localized in the human Jurkat T cell 
line using confocal microscopy [23].   
 
Effect of ZnO NP Size on Cytotoxicity and ROS Production 
To evaluate the relationship between ZnO NP size and its toxic potential, three different sizes of ZnO NPs 
(4nm, 13nm, and 20nm) were concurrently evaluated using primary human CD4+ T cells as a model 
system. Experiments shown in Figure 6A were performed using a NP concentration of 5 mM, given the 
observed IC50 value for T cells observed above.  These experiments demonstrate that significantly greater 
cytotoxicity was observed with 4-nm NPs (80.0% ± 2.0%), compared to either 13-nm or 20-nm sized NPs 
(p=0.04 and p=0.01, respectively). In addition, significantly more cytotoxicity (p=0.05) was observed for 
13 nm NPs (70.1% ± 8.0%), compared to 20-nm NPs (44.0% ± 6.8%). To further verify that cytotoxicity 
increases with decreasing NP size, experiments were performed over a range of NP concentrations. As 
shown in Figure 6B, significantly greater toxicity was observed using 4-nm NPs compared to 20-nm NP at 
all concentrations tested (p = 0.03 at 1 mM, p = 0.0001 at 5 mM and p = 0.01 at 10 mM NP concentration).  
In this paper, we have focused on the size-dependence cytotoxicity of NPs.  However, as shown in the inset 
to Figure 2, the aspect ratio of NPs increases with size.  Therefore, the role of shape morphology on NP 
cytotoxic response will be the subject of future investigations. 
 
To further evaluate the mechanism of nanotoxicity, studies were performed to investigate the relationship 
between size dependence and ZnO NP-induced ROS production using PBMC cell cultures.  Following a 3h 
treatment with different-sized ZnO NPs (4-nm, 13-nm and 20-nm), a size-dependent induction of ROS was 
observed at both NP concentrations, with 4-nm sized NPs consistently inducing higher levels of ROS 
compared to 13-nm or 20-nm sized NPs (Figure 7).  At 5 mM NP concentrations, significantly higher levels 
of ROS were observed for 4-nm and 13-nm NPs compared to 20-nm NPs (∼4-fold relative increase (p = 
0.005) and ∼3-fold increase (p = 0.01), respectively). Similarly, 10 mM NP treatment resulted in significant 
differences in ROS production between all sizes of NP with a 3.2-fold greater induction of ROS observed 
between 4-nm and 20-nm NPs (p= 0.001), and a 1.9-fold increase observed between 13-nm and 20-nm NPs 
(p = 0.0021).  This findings indicate that the generation of ROS is dependent on NP size. 
 
  
C. Hanley, A. Thurber, C. Hanna, A. Punnoose, J. Zhang, & D. G. Wingett in NANOSCALE RESEARCH LETTERS (2009)  8 
This is an author-produced, peer-reviewed version of this article.  The final, definitive version of this document can be found online 
at Nanoscale Research Letters, published by Springer.  Copyright restrictions may apply.  doi: 10.1007/s11671-009-9413-8 
The increased nanotoxicity with decreasing NP size may be due in part to, the larger surface area/volume 
ratio of smaller NPs which provides them with a greater area to associate with cellular membranes and 
proteins, as well as greater surface reactivity. In addition, ZnO particles prepared in a nonaqueous medium 
may have oxygen deficient/zinc rich surface chemistries [10] that exhibit strong electrostatic interactions 
with the negatively charged cell membrane [31,32], with smaller particles predicted to have a greater 
positive surface charge to volume ratio. Thus, greater initial cell membrane-NP association would be 
expected for smaller NP, leading to potentially greater intracellular uptake.   
 
Following initial NP-cell electrostatic interactions, mechanisms of toxicity likely proceed via the formation 
of highly reactive oxygen species, such as hydrogen peroxide, hydroxyl radical, and superoxide anion 
[2,16]. The ability of smaller-sized ZnO NPs to promote greater levels of ROS may occur because as ZnO 
NP size decreases, so does the nanocrystal quality, which results in increased interstitial zinc ions and 
oxygen vacancies [33].  These crystal defects lead to a large number of electron-hole pairs (e- - h+) which 
are typically activated by both UV and visible light.  However, for nanoscale ZnO, large numbers of 
valence band holes and/or conduction band electrons are thought to be available to serve in redox reactions 
even in the absence of UV irradiation [17] . The holes can split water molecules derived from the ZnO 
suspension into H+ and OH-. The resulting electrons react with dissolved oxygen molecules to generate 
superoxide radical anions (•O2-), which in turn react with H+ to generate (HO2•) radicals.  These HO2• 
molecules can then produce hydrogen peroxide anions (HO2-) following a subsequent encounter with 
electrons. Hydrogen peroxide anions can then react with hydrogen ions to produce hydrogen peroxide 
(H2O2) [7,34].  
ZnO + hv →  ZnO + e- + h+   ;  h+  + H2O   →  •OH + H+ 
e- + O2  → •O2-   ;  •O2- + H+ → HO2•   ;  HO2•  + H+  + e- →  H2O2 
All of the various ROS molecules produced in this fashion can trigger redox-cycling cascades in the cell, or 
on adjacent cell membranes.  This can then lead to the depletion of endogenous cellular reserves of 
antioxidants such that irreparable oxidative damage occurs to cellular biomolecules and eventually results 
in cell death.  
 
ZnO NP Induce Pro-Inflammatory Cytokine Production in Primary Human Immune Cells  
  
An important task of nanobiotechnology is to understand the effect these nanomaterials have to modulate 
expression of cytokines, which are soluble biological protein messengers that regulate the immune system. 
Published studies have demonstrated the ability of certain nanomaterials to induce cytokine production, 
although this appears heavily dependent on a variety of factors, including material composition, size, and 
method of delivery [35,36].  Much remains to be learned, however, regarding the pro-inflammatory 
potential of ZnO NPs. To address this gap in knowledge, studies were performed to evaluate the ability of 
ZnO NPs to modulate IFN-γ, TNF-α and IL-12 cytokine production in primary human immune cells. 
These particular cytokines were chosen because they represent critical pathways involved in the 
inflammatory response and differentiation processes. Freshly isolated PBMC were treated with varying 
concentrations of 8-nm ZnO NPs for 38h, and cell-free supernatants were used to quantitate cytokine levels 
using an ELISA. For IL-12 production, cell samples were first pre-treated with IFN-γ (1000 U/mL) before 
addition of NPs to provide a priming signal for IL-12 [37]. Results demonstrate significant dose-dependent 
increases in IFN-γ and TNF-α at all NP concentrations tested (0.05 mM, 0.1 mM and 0.2 mM) (Figure 8). 
ZnO NPs had no effect on IL-12 production in unprimed control cultures, but pretreatment with low level 
IFN-γ prior to NP exposure resulted in appreciable amounts of IL-12 in a concentration-dependent manner. 
The inability of ZnO NPs to induce IL-12 in resting cells was not altogether unexpected, as expression of 
this cytokine typically occurs in cells that have first received a priming signal, such as IFN- γ, which is 
locally produced by other cells participating in the immune response [37]. These results suggest that a 
synergistic relationship between ZnO NPs and IFN-γ may occur in in vivo settings employing ZnO NPs, 
and demonstrate that ZnO NPs are capable of inducing at least some key components of inflammation. 
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The ability of ZnO NPs to induce proinflammatory cytokine expression in human primary immune cells is 
consistent with the recognized relationship between oxidative stress and inflammation, which is partially 
mediated by induction of the NF-κB transcription factor [38]. To date, only limited studies have evaluated 
the effects of ZnO NPs on cytokine production, and most of these studies have been conducted in non-
hematological cell types or in immortalized cell lines which frequently display alterations in signal 
transduction pathways, leading to unpredictable changes in protein expression.  In one report, ZnO NPs 
were shown to increase IL-8 and MCP-1 cytokine mRNA expression in human aortic endothelial cells, 
although no information was provided regarding changes in corresponding protein levels [39].  In two other 
studies conducted in immortalized rodent lung epithelial cells, alveolar macrophage cell lines and primary 
aleveolar macrophages, ZnO NPs fail to induce TNF-α at concentrations exceeding those used in this study 
[36,40]. In addition, no changes in other cytokines and chemokines including IL-6, G-CSF, MIP-2, 
CXCL10, and CCL2 were detected. The ability of ZnO NPs to induce high levels of TNF-α in our studies 
may be due to differing responses observed between cell populations studied (i.e., PBMC vs. alveolar 
macrophages), or reflect the longer NP treatment exposure period (i.e.,  38h vs. 24h). Although, to the best 
of our knowledge, no published studies have demonstrated the ability of ZnO NPs to induce TNF-α or IL-6 
production in purified primary cell cultures or in toxicological evaluations, it is interesting to note that 
inhalation of ultrafine ZnO particles in occupational settings can increase the expression of these cytokines, 
which is symptomatically recognized as metal fume fever in welders (e.g., fatigue, fever, chills, myalgias, 
cough, and leukocytosis) [16]. 
 
The ability of ZnO NPs to induce IL-12, IFN-γ, and TNF-α at NP concentrations below those causing 
appreciable cytotoxicity indicates immunomodulatory effects that may function to bias the immune 
response towards Th1-mediated immunity. It is the cytokine profile that directs the development and 
differentiation of T helper cells into the two different subsets, called type 1 (Th1) and type 2 (Th2) [41,42]. 
Th1 cells are recognized to play an essential role in promoting innate and cell-mediated immunity, while 
Th2 cells promote antibody-based humoral responses [41].  Relevant to our findings, IL-12 and IFN-γ play 
critical roles in Th1 development, and help set-up a perpetuating loop whereby more Th1 development is 
favored, Th2 development is suppressed, and the cytotoxicity activity of both NK cells and T cytotoxic 
cells against cancerous cells, virally infected cells, or intracellular pathogens is enhanced [42].  Thus, our 
findings indicate that careful titration of ZnO NP-based therapeutic interventions may be successful in 
elevating a group of cytokines important for eliciting a Th1-mediated immune response with effective anti-
cancer actions.  These results, combined with our previous observations demonstrating that immortalized 
hematopoietic cancer cells are preferentially killed (~33-fold) by ZnO NPs compared to normal cells of 
identical lineage [13], suggest that ZnO NPs may function via a two-fold mechanism to eliminate cancer 
cells by direct and preferential cytotoxic actions, and by enhancing the type of immunity most effective at 
eliciting an in vivo anti-cancer response.  
The ability of ZnO NPs to induce TNF-α may also help promote Th1 differentiation [41,43] as well as 
functioning as a regulator of acute inflammation [44]. Notably, this cytokine received its name based on its 
potent in vitro and in vivo anti-tumor activity. However, high level and/or chronic exposure to TNF-α has 
been shown to produce serious detrimental effects on the host, including septic shock or symptoms 
associated with autoimmune disease [44]. Our results demonstrate significant dose-dependent increases in 
TNF-α over a somewhat narrow range of ZnO NP concentrations.  The magnitude of TNF-α induction, as 
well as other pro-inflammatory cytokines, and their local-regional delivery to tumor sites or other desired 
areas, will undoubtedly be important parameters when considering ZnO NP for biomedical purposes to 
achieve the desired therapeutic response without eliciting potential systemic damaging effects from these 
cytokines.  
 
Conclusions 
 
Results from these studies demonstrate that ZnO NPs induce toxicity in a cell-type specific manner that is 
dependent on the degree of NP-cellular membrane association, phagocytic ability, and inherent cellular 
capacities for ROS production.  Monocytic cells displayed the greatest susceptibility and intracellular ROS 
production following NP exposure, followed by NK cells, followed by lymphocytes, which displayed the 
most resistance.  Studies employing ROS quenchers implicate ROS formation as a major mechanism of 
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ZnO NP-induced toxicity, and demonstrate that the generation of ROS and the cytotoxic profile occurs in a 
NP size-dependent manner, with smaller NPs displaying the greatest effect. The variable responses of 
immune cells described in this study underscore the need for careful in vitro evaluation across a spectrum 
of relevant cell types, followed by appropriate in vivo studies to provide useful and potentially predictive 
screening data regarding the relative toxicity effects of metal-oxide NPs.  These factors are also important 
considerations for the potential incorporation of ZnO NPs into novel nanotechnology-based biological 
applications.   
 
Our results demonstrating that ZnO NPs can induce the expression of immunoregulatory cytokines is also a 
relevant consideration for potential use in biomedical applications, as many current treatments for human 
disease function by manipulating and controlling components of the immune response [45].  To the best of 
our knowledge, our results appear to be the first to document the ability of ZnO NPs to increase the 
expression of IFN-γ, TNF-α, and IL-12 in primary immune human cells, and at NP concentrations below 
those causing appreciable cell death. These findings suggest that ZnO NPs, when used at appropriate 
concentrations, could directly enhance tumor cell killing through the production of TNF-α, and could also 
facilitate effective anti-cancer actions by eliciting a cytokine profile crucial for directing the development 
of Th1-mediated immunity. The in vivo therapeutic window for ZnO NP to increase proinflammatory 
cytokines indicates that parameters controlling ZnO NP toxicity, such as particle size, concentration, and 
biodistribution will need to be carefully controlled when considering metal-oxide NPs for use in biological 
applications, especially given the recognized relationship of chronic inflammatory processes and 
tumorigenesis. Future studies are needed to investigate the effects of ZnO NPs on additional cytokines and 
inflammatory mediators, as well as mechanisms of NP cellular uptake and ROS formation.  
Figure Legends 
Figure 1. TEM images of ZnO nanoparticle samples made using the hydrolysis molar ratio (water:zinc 
acetate) of 2.4 (panel a), 6.1 (panel b), 12.2 (panel c), and 24.4 (panel d). Panel (e) shows the corresponding 
size distribution of the samples shown in panel a (4 nm), panel b (8 nm), panel c (13 nm) and panel d (20 
nm). Panel (e) shows a histogram obtained from TEM data demonstrating particle size distribution. 
 
Figure 2.  X-ray diffraction θ-2θ scans of powder samples of various sizes of ZnO nanoparticles recorded 
in air at room temperature.  The x-ray source used was Cu Kα with an effective wavelength λ = 1.5418 Å.  
The peak widths are inversely related to the crystallite sizes according to the Scherrer relation, enabling the 
XRD patterns to demonstrate the change in particle size.  The stick pattern from reference data for wurtzite 
ZnO is shown along the x-axis (represented by the solid squares) and fully indexes the experimental data.  
The inset shows the relationship between average crystallite size (L) and average aspect ratio (AR) of 
several samples, prepared using the synthesis method employed in this work, as determined by XRD.  AR 
was calculated from the widths of the (100) and (002) XRD peaks, and excludes data for 4 nm samples due 
to the amount of peak overlap. 
 
Figure 3. Differential cytotoxic effects of ZnO NPs on human immune cell subsets. A) PBMC were treated 
with varying concentrations of 8-nm ZnO NPs for 24h and viability of CD3+ T cells, CD4+ T cells, B cells, 
NK cells, and monocytes present in same PBMC cultures determined by monitoring PI uptake using flow 
cytometry. Data from three independent experiments is presented with error bars depicting standard error 
(s.e.).  Asterisks denote statistically significant (p<0.05) differences between CD3+ T cells, B cells, NK 
cells and monocytes at indicated NP concentrations as determined using a repeated measures ANOVA.  B) 
ZnO NP toxicity on purified human primary monocytes. Purified human peripheral blood CD14+ 
monocytes were treated with varying concentrations of ZnO NPs (0.0625 -1 mM) and viability assessed 
using the Alamar Blue cytotoxicity assay with error bars representing s.e., (n=4). The IC50 was determined 
using non-linear regression analysis. 
 
Figure 4. Differential ZnO NP cytotoxicity between naïve and memory T cells. Human peripheral blood 
PBMC were left untreated or treated with 10 mM ZnO NPs (8-nm) for 22-24h and viability determined by 
monitoring PI uptake using flow cytometry.  T cells were defined as CD3+, naïve T cells as  
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CD3+,CD45RA+,  and memory T cells as CD3+,CD45RO+ .  Data from three independent experiments is 
presented and error bars depict s.e. Asterisks denote statistically significant differences (p<0.05) between 
NP treatment groups using as a one-way repeated measures ANOVA.   
 
Figure 5.  Quenching of ROS rescues T cells and monocytes from ZnO NP-induced cytotoxicity. Purified 
peripheral blood CD14+ monocytes (≥ 96%purity) and CD4+ T cells (≥ 95% purity) were pretreated for 4-6 
hr with 5 mM N-acetyl cysteine (NAC) or vehicle control and then subsequently cultured with 8-nm sized 
ZnO NPs, or left untreated for 24 hr. Viability was assessed using the Alamar Blue cytotoxicity assay. A) 
Purified monocytes treated with 0.125 mM ZnO NPs ± 5 mM NAC, n=3. B) Isolated CD4+ T cells  treated 
with 5 mM ZnO NPs ±  5 mM NAC, n=3. Asterisks denote statistically significant differences (p<0.05) as 
analyzed using a 2-way ANOVA and error bars depict s.e.  
 
Figure 6. Effect of NP size on cytotoxicity. A) Purified human CD4+ T cells (>97% purity) were left 
untreated or incubated with different sizes (4, 13, and 20 nm) of ZnO NPs at a final concentration of 5 mM. 
Following culture for 22-24 hr, viability was determined using PI uptake and flow cytometry, n=4. B) 
Cytotoxicity studies in purified human CD4+ T cells were performed using varying concentrations (1-10 
mM) of  4-nm and 20-nm sized ZnO NPs, n=4.   Error bars depict s.e. and asterisks indicate statistically 
significant differences (p<0.05) as determined by repeated measures ANOVA.  
 
Figure 7. Effects of NP size on ROS production in peripheral blood immune cells. Primary human PBMC 
were treated with two different concentrations of ZnO NPs (5 mM and 10 mM) for 3h and ROS production 
evaluated using a fluorescent microplate reader. Data from a representative experiment is shown (n = 3) 
with error bars depicting s.e.  Data was analyzed using a 2-way ANOVA and asterisks denote statistical 
significance as defined by p<0.05.  
 
Figure 8. ZnO NPs increase pro-inflammatory cytokine production in primary human peripheral blood 
cells. PBMC were left untreated or treated with varying concentrations of 8-nm ZnO NPs, both alone or 
with the addition of exogenous IFN-γ (1000 U/mL),for 38h. Cytokine production was evaluated by ELISA 
and data analyzed using a 2-way ANOVA.  Error bars depicting s.e., n=3. Astericks denote statistically 
significant differences as defined as p<0.05. 
 
Table 1. Freshly isolated PBMC were treated with 1mM and 5 mM of 8-nm sized ZnO NPs and ROS 
production measured using the oxidation sensitive DCFH-DA probe.  Following NP treatment for 6h or 
20h, cells were loaded with DCFH-DA and flow cytometry used to simultaneously evaluate ROS 
production and distinguish T cells and monocytes present in PBMC cultures by staining with fluorescently 
labeled CD3 and CD14 antibodies. Values indicate the percentage of ROS producing cells ± s.e., n=3. 
 
Table 2. Freshly isolated PBMC were left untreated or exposed to 5 mM FITC-encapsulated ZnO NPs for 
15h. The cell mixture was then stained with fluorescently labeled CD3, CD4, CD19, CD14 antibodies to 
identify subsets, washed to remove excess antibody and unbound NPs, and the level of NP association 
determined based on FITC fluorescent signal using flow cytometry. Data was obtained by gating on 10,000 
events, n=3.   
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